New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic

Salix Pharmaceuticals Sponsored Report,   Patient Perspectives: Living with IBS in a Pandemic

Insights May Help Health Care Providers Have Productive Conversations with Their Patients About IBS Symptoms

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today released a report of survey results that offers perspectives from U.S. adults living with irritable bowel syndrome (IBS) during the COVID-19 pandemic. Entitled Patient Perspectives: Living with IBS in a Pandemic the report provides insights about the symptoms and behaviors of IBS patients over the past year ( March 2020 March 2021 ). Most notably, more than one-third (37%) of those surveyed acknowledge that the COVID-19 pandemic has made it more challenging to manage their IBS symptoms. The report, which was developed based on a survey conducted by The Fairleigh Dickinson University Poll, also finds concerns about post-pandemic life and insights about the way patients are communicating with their health care providers.

Experience the interactive Multimedia News Release here:
https://www.multivu.com/players/English/8700351-salix-pharmaceuticals-survey-living-with-ibs-in-a-pandemic

Salix_Logo

"It's been just over a year since the COVID-19 pandemic upended lives across the nation. Salix is committed to helping patients with GI conditions, and we believe it is important to gain an understanding of how the COVID-19 pandemic may impact people living with IBS, a common gastrointestinal disorder that is estimated to affect more than 12 million Americans 1 ," said Robert Spurr , president, Salix Pharmaceuticals. "We believe these new insights may foster important dialogue between health care providers and their patients."

Key findings from the report include:

  • The pandemic is impacting the wellbeing of IBS patients with 49% reporting that their mental health has worsened. Of the respondents, 51% report worse physical activity and 34% state worse eating habits.
  • Many respondents report deteriorating IBS symptoms. According to the survey, 33% report worsened diarrhea, 31% report worsened constipation, 39% report worsened abdominal pain or discomfort, and 42% report worsened bloating.
    • Fewer than 15% of patients surveyed living with these symptoms report experiencing an improvement over the past year.
  • 35% of respondents have not discussed their IBS symptoms with a health care provider at all since the COVID-19 pandemic began.
  • Respondents express concerns about post-pandemic life, including lack of access to restrooms (55%) and being able to attend social gatherings (48%).

To view the complete findings from the Patient Perspectives: Living with IBS in a Pandemic report, visit https://www.multivu.com/arc/preview/English/5aa7d9e2-941f-4598-b913-68d833d98c4a/docs/SurveyResults_1618414718263-8129634.pdf .

About the Methodology Behind Patient Perspectives: Living with IBS in a Pandemic  
Data is from a representative non-probability online sample of U.S. residents and was carried out in March 2021 by Fairleigh Dickinson University's FDU Poll. Participants were recruited based on previously reported gastrointestinal issues. The overall sample size of the survey was 695 respondents and was screened to include only those who self-reported having IBS with constipation, Chronic Idiopathic Constipation or IBS with diarrhea. Respondents were drawn from multiple panels of U.S. residents and were compensated for their time. Due to the limitations of this survey, results may not be representative of the general IBS population.

About Fairleigh Dickinson University  
Since 2001, Fairleigh Dickinson University's FDU Poll has conducted survey research on issues of public importance. Utilizing best practices in survey methodology, FDU Poll produces authoritative statewide and national public polling. In addition, FDU Poll engages in research for corporate, non-profit and government entities. As a charter member of the American Association for Public Opinion Research's Transparency Initiative, the FDU Poll is devoted to building public confidence in polling by embracing the open science of survey research.

About Salix  
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey . For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn .

About Bausch Health  
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration, and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

References

  1. Palsson OS, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States , Canada , and the United Kingdom . Gastroenterology. 2020 Apr;158(5):1262-1273.e3. doi: 10.1053/j.gastro.2019.12.021. Epub 2020 Jan 7 . PMID: 31917991.

SAL.0059.USA.21
©2021 Salix Pharmaceuticals or its affiliates.

Bausch_Health_Logo

Cision View original content: https://www.prnewswire.com/news-releases/new-report-reveals-that-more-than-one-third-of-ibs-patients-surveyed-state-it-has-been-more-challenging-to-manage-their-symptoms-during-the-covid-19-pandemic-301269331.html

SOURCE Salix Pharmaceuticals

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Bausch Health Companies Inc.

Bausch Health Companies Inc.

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.

illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×